文献速递乳腺癌放疗

外照射加速部分乳腺照射每日分割至40 Gy耐受良好且局部有效

Daily Fractionation of External Beam Accelerated Partial Breast Irradiation to 40 Gy Is Well Tolerated and Locally Effective.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-03-07

研究前瞻性纳入106例保乳术后淋巴结阴性乳腺导管原位癌或浸润性癌患者,接受三维适形外照射加速部分乳腺照射(APBI)40 Gy分10次每日照射。中位随访58个月,16例(15%)出现≥2级皮肤毒性,仅2例3级毒性,3例乳腺癌复发,99%患者美容效果优/良。

要点

  • APBI 40 Gy分10次每日照射,≥2级皮肤毒性16/106(15%),3级毒性仅2例。
  • 计划靶体积和乳腺V20显著预测皮肤/皮下毒性,限制乳腺V20<45%可能改善耐受性。
  • 3例乳腺癌复发:原象限局部1例(3年)、同侧不同象限1例(5年)、远处转移1例(2年)。

核心结论

  • 在适当选择的早期乳腺癌患者中,APBI 40 Gy分10次每日照射耐受良好,99%患者报告美容效果优/良。
  • 应仔细限制计划靶体积和乳腺V20以减少局部并发症,需更长随访确定疗效和后续局部复发率。

研究设计与样本

  • 前瞻性研究,2010年至2014年纳入106例保乳术后淋巴结阴性乳腺浸润性或原位癌患者,接受三维适形外照射APBI 40 Gy分10次每日照射。

主要发现

  • 中位年龄62岁(范围39-85),中位随访58个月。
  • 106例中16例(15%)发生≥2级皮肤毒性,最常见为放疗后4-9周急性皮肤改变,包括2级红斑2例(1.8%)和皮肤颜色改变4例(3.8%)。
  • 仅报告2例3级毒性,包括1例放疗后急性湿性脱屑和1例2年时纤维化。
  • 计划靶体积和乳腺V20显著预测皮肤/皮下毒性,有证据表明限制乳腺V20<45%可能改善耐受性。
  • 共3例乳腺癌复发:原象限局部复发1例(APBI后3年)、同侧不同象限1例(APBI后5年)、远处转移1例(APBI后2年)。

关键数值与推荐

  • APBI总剂量40 Gy分10次每日照射。
  • 计划靶体积和乳腺V20显著预测皮肤/皮下毒性,限制乳腺V20<45%可能改善耐受性。

临床怎么用

  • 在适当选择的早期乳腺癌患者中,APBI 40 Gy分10次每日照射耐受良好,99%患者美容效果优/良。
  • 应仔细限制计划靶体积和乳腺V20以限制局部并发症。

局限性

  • 需更长随访确定疗效和后续局部复发率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Most studies examining accelerated partial breast irradiation (APBI) have used twice-daily fractionation. Cosmesis with this approach has produced mixed results, and the optimal fractionation scheme remains unknown. We sought to evaluate the safety and efficacy of APBI with a total dose of 40 Gy in 10 daily fractions. METHODS AND MATERIALS: Between 2010 and 2014, we prospectively enrolled 106 patients to receive APBI after lumpectomy for invasive or in situ node-negative breast cancer. Radiation was administered via 3-dimensional conformal techniques. RESULTS: The median age was 62 years (range, 39-85), and all patients underwent APBI per protocol. With a median follow-up of 58 months, we evaluated patient-reported local toxicity and recurrence outcomes. Of 106 patients, 16 (15%) experienced grade ≥2 skin toxicity. The most common significant toxicities were acute cutaneous changes at 4 to 9 weeks after radiation therapy, including grade 2 erythema in 2 patients (1.8%) and skin color changes in 4 patients (3.8%). Only 2 instances of grade 3 toxicity were reported, including 1 patient with acute moist desquamation after radiation therapy and another with fibrosis at 2 years. Planning target volume and breast V20 were significantly predictive of skin/subcutaneous toxicity, with evidence that limiting breast V20 to <45% may improve tolerability. Overall, 3 breast cancer recurrences arose: 1 local recurrence in the original quadrant (3 years after APBI), 1 in a different ipsilateral quadrant (5 years after APBI), and 1 with distant disease 2 years after APBI. CONCLUSIONS: In an appropriately selected group of patients with early stage breast cancer, APBI to a dose of 40 Gy in 10 daily fractions was well tolerated, with most patients (99%) reporting excellent/good cosmesis. Planning target volume and breast V20 should be carefully constrained to limit local morbidity. Longer follow-up will be needed to establish efficacy and subsequent local recurrence rates.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Braunstein LZ, Thor M, Flynn J, et al. Daily Fractionation of External Beam Accelerated Partial Breast Irradiation to 40 Gy Is Well Tolerated and Locally Effective. Int J Radiat Oncol Biol Phys. 2019. PMID: 30851350. doi:10.1016/j.ijrobp.2019.02.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。